Platelet immunology in fungal infections

Thrombosis and Haemostasis

Volumn 112, Issue 4, 2014, Pages 632-639

  Speth, Cornelia ^a   Rambach, Günter ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Fungi; Innate immunity; Invasive infection; Platelets

Indexed keywords

AMPHOTERICIN B; ANAPHYLATOXIN; ANIDULAFUNGIN; CASPOFUNGIN; CYTOSTATIC AGENT; ECHINOCANDIN; FLUCONAZOLE; PENICILLIN DERIVATIVE; POSACONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; COMPLEMENT;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COMPLEMENT SYSTEM; CRYPTOCOCCUS; FUNGUS TRANSMISSION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLAMMATION; INTENSIVE CARE UNIT; LICHTHEIMIA; MUCOR; MYCOSIS; NONHUMAN; RHIZOMUCOR; RHIZOPUS; SYSTEMIC MYCOSIS; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; ASPERGILLUS; BLOOD; CANDIDA; CHEMISTRY; CYTOLOGY; FILOBASIDIELLA; IMMUNE SYSTEM; INNATE IMMUNITY;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ASPERGILLUS; BLOOD PLATELETS; CANDIDA; COMPLEMENT SYSTEM PROTEINS; CRYPTOCOCCUS; CYTOSTATIC AGENTS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFLAMMATION; MYCOSES;

EID: 84908554166     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-01-0074     Document Type: Article

References (90)

1. Semple JW, Italiano JE, Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
2. Coppinger JA, Maguire PB. Insights into the platelet releasate. Curr Pharm Des 2007; 13: 2640-2646.
3. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 Suppl 1: S13-S33.
4. Speth C, Loffler J, Krappmann S, et al. Platelets as immune cells in infectious diseases. Future Microbiol 2013; 8: 1431-1451.
5. Garraud O, Cognasse F. Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation. Inflamm Allergy Drug Targets 2010; 9: 322-333.
6. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010; 67: 499-511.
7. Tapping RI. Innate immune sensing and activation of cell surface Toll-like receptors. Semin Immunol 2009; 21: 175-184.
8. Shiraki R, Inoue N, Kawasaki S, et al. Expression of Toll-like receptors on human platelets. Thromb Res 2004; 113: 379-385.
9. Krijgsveld J, Zaat SA, Meeldijk J, et al. Thrombocidins, mirobiocidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 275: 20374-20381.
10. Yount NY, Yeaman MR. Peptide antimicrobials: cell wall as a bacterial target. Ann NY Acad Sci 2013; 1277: 127-138.
11. Youssefian T, Drouin A, Masse JM, et al. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 2002; 99: 4021-4029.
12. Czapiga M, Kirk AD, Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp Hematol 2004; 32: 135-139.
13. Gerdes N, Zhu L, Ersoy M, et al. Platelets regulate CD4(+) T-cell differentiation via multiple chemokines in humans. Thromb Haemost 2011; 106: 353-362.
14. Kasper B, Brandt E, Brandau S, et al. Platelet factor 4 (CXC chemokine ligand 4) differentially regulates respiratory burst, survival, and cytokine expression of human monocytes by using distinct signaling pathways. J Immunol 2007; 179: 2584-2591.
15. Maugeri N, Rovere-Querini P, Evangelista V, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and {beta}2 integrindependent cell clearance program. Blood 2009; 113: 5254-5265.
16. Sprague DL, Elzey BD, Crist SA, et al. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008; 111: 5028-5036.
17. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489-495.
18. Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol 2012; 34: 5-30.
19. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
20. Scull CM, Hays WD, Fischer TH. Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflamm 2010; 7: 53.
21. Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 2007; 35: 1376-1387.
22. Hamzeh-Cognasse H, Cognasse F, Palle S, et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol 2008; 9: 54.
23. Lass-Flörl C. The changing face of epidemiology of invasive fungal diseases in Europe. Mycoses 2009; 52: 197-205.
24. Rambach G, Speth C, Lass-Flörl C. Changing epidemiology of invasive fungal infections in critically ill patients in the intensive care unit. J Invas Fungal Infect 2010; 3: 116-122.
25. Guimaraes MD, Marchiori E, de Souza Portes MG, et al. Fungal infection mimicking pulmonary malignancy: clinical and radiological characteristics. Lung 2013; 191: 655-662.
26. Cadelis G. [Hemoptysis complicating bronchopulmonary mucormycosis in a diabetic patient]. Rev Pneumol Clin 2013; 69: 83-88.
27. Guazzelli LS, Severo CB, Hoff LS, et al. Aspergillus fumigatus fungus ball in the pleural cavity. J Bras Pneumol 2012; 38: 125-132.
28. Kamai Y, Chiang LY, Lopes Bezerra LM, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol 2006; 44 (Suppl 1): S115-S117.
29. Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 2014; 5: 161-169.
30. van de Veerdonk FL, Kullberg BJ, Netea MG. Pathogenesis of invasive candidiasis. Curr Opin Crit Care 2010; 16: 453-459.
31. Attigah N, Herpel E, Kotelis D, et al. Endovascular repair of aspergilloma-induced arrosion bleeding of the subclavian artery. Chirurg 2008; 79: 984-987.
32. Sorgo AG, Heilmann CJ, Brul S, et al. Beyond the wall: Candida albicans secret(e)s to survive. FEMS Microbiol Lett 2013; 338: 10-17.
33. Girard V, Dieryckx C, Job C, et al. Secretomes: the fungal strike force. Proteomics 2013; 13: 597-608.
34. Fontaine T, Delangle A, Simenel C, et al. Galactosaminogalactan, a new immunosuppressive polysaccharide of Aspergillus fumigatus. Plos Pathog 2011; 7: e1002372.
35. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519-531.
36. Hsu JL, Ruoss SJ, Bower ND, et al. Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol 2011; 37: 277-312.
37. Roeder A, Kirschning CJ, Rupec RA, et al. Toll-like receptors and innate antifungal responses. Trends Microbiol 2004; 12: 44-49.
38. Bertling A, Niemann S, Uekotter A, et al. Candida albicans and its metabolite gliotoxin inhibit platelet function via interaction with thiols. Thromb Haemost 2010; 104: 270-278.
39. Lass-Flörl C, Wiedauer B, Mayr A, et al. Antifungal properties of 5-HT (serotonin) against Aspergillus spp. in vitro. Int J Med Microbiol 2005; 26: 335-337.
40. Flaujac C, Boukour S, Cramer-Borde E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci 2010; 67: 545-556.
41. Stone D, Liu Y, Shayakhmetov D, et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol 2007; 81: 4866-4871.
42. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
43. Kullberg BJ, Lashof AML. Epidemiology of opportunistic invasive mycoses. Eur J Med Res 2002; 7: 183-191.
44. Christin L, Wysong DR, Meshulam T, et al. Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils. Infect Immun 1998; 66: 1181-1189.
45. Rodland EK, Ueland T, Pedersen TM, et al. Activation of platelets by Aspergillus fumigatus and potential role of platelets in the immunopathogenesis of Aspergillosis. Infect Immun 2010; 78: 1269-1275.
46. Perkhofer S, Kehrel BE, Dierich MP, et al. Human platelets attenuate Aspergillus species via granule-dependent mechanisms. J Infect Dis 2008; 198: 1243-1246.
47. Speth C, Hagleitner M, Ott HW, et al. Aspergillus fumigatus Activates Thrombocytes by Secretion of Soluble Compounds. J Infect Dis 2013; 207: 823-833.
48. Nouer SA, Nucci M, Kumar NS, et al. Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis. Clin Infect Dis 2012; 54: e173-e183.
49. Speth C, Blum G, Hagleitner M, et al. Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility. Med Microbiol Immunol 2013; 202: 379-389.
50. Rambach G, Oberhauser H, Speth C, et al. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. Med Mycol 2011; 49: 856-863.
51. Maisch PA, Calderone RA. Adherence of Candida albicans to a fibrin-platelet matrix formed in vitro. Infect Immun 1980; 27: 650-656.
52. Robert R, Mahaza C, Miegeville M, et al. Binding of resting platelets to Candida albicans germ tubes. Infect Immun 1996; 64: 3752-3757.
53. Robert R, Nail S, Marot-Leblond A, et al. Adherence of platelets to Candida species in vivo. Infect Immun 2000; 68: 570-576.
54. Willcox M, Webb B, thakur A, et al. Interactions between Candida species and platelets. J Med Microbiol 1998; 47: 103-110.
55. Woth G, Tokes-Fuzesi M, Magyarlaki T, et al. Activated platelet-derived microparticle numbers are elevated in patients with severe fungal (Candida albicans) sepsis. Ann Clin Biochem 2012; 49: 554-560.
56. Carvalho Neiva TJ, dos Santos JI. Effect of pathogenic yeasts on human platelet aggregation. Braz J Infect Dis 2003; 7: 370-374.
57. Drago L, Bortolin M, Vassena C, et al. Antimicrobial activity of pure plateletrich plasma against microorganisms isolated from oral cavity. BMC Microbiol 2013; 13: 47.
58. Kwakman PH, Krijgsveld J, de BL, et al. Native thrombocidin-1 and unfolded thrombocidin-1 exert antimicrobial activity via distinct structural elements. J Biol Chem 2011; 286: 43506-43514.
59. Tang Y, Yeaman M, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6524-6533.
60. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl 1): S23-S34.
61. Perkhofer S, Kainzner B, Kehrel BE, et al. Potential antifungal effects of human platelets against zygomycetes in vitro. J Infect Dis 2009; 200: 1176-1179.
62. Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011; 32: 693-702.
63. Nail S, Robert R, Dromer F, et al. Susceptibilities of Cryptococcus neoformans strains to platelet binding in vivo and to the fungicidal activity of thrombin-induced platelet microbicidal proteins in vitro. Infect Immun 2001; 69: 1221-1225.
64. Rambach G, Wurzner R, Speth C. Complement: an efficient sword of innate immunity. Contrib Microbiol 2008; 15: 78-100.
65. Speth C, Rambach G. Complement Attack against Aspergillus and Corresponding Evasion Mechanisms. Interdiscip Perspect Infect Dis 2012; 2012: 463794.
66. Speth C, Prodinger W, Würzner R, et al. Complement. In: Fundamental Immunology. 6th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2008; pp. 1047-1078.
67. Del Conde I, Cruz MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879.
68. Peerschke EI, Yin W, Grigg SE, et al. Blood platelets activate the classical pathway of human complement. J Thromb Haemost 2006; 4: 2035-2042.
69. Hamad OA, Ekdahl KN, Nilsson PH, et al. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J Thromb Haemost 2008; 6: 1413-1421.
70. Hamad OA, Nilsson PH, Lasaosa M, et al. Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One 2010; 5: e12889.
71. Peerschke EI, Andemariam B, Yin W, et al. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 2010; 148: 638-645.
72. Peerschke EI, Yin W, Alpert DR, et al. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2009; 18: 530-538.
73. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170-2175.
74. Langeggen H, Berge KE, Johnson E, et al. Human umbilical vein endothelial cells express complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro. Inflammation 2002; 26: 103-110.
75. Skeie JM, Fingert JH, Russell SR, et al. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2010; 51: 5336-5342.
76. Ikeda K, Nagasawa K, Horiuchi T, et al. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-398.
77. Ward PA. The harmful role of c5a on innate immunity in sepsis. J Innate Immun 2010; 2: 439-445.
78. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 1986; 68: 875-880.
79. Verschoor A, Langer HF. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 2013; 110: 910-919.
80. Yeaman M, Sullam P, Dazin P, et al. Fluconazole and platelet microbicidal protein inhibit Candida adherence to platelets in vitro. Antimicrob Agents Chemother 1994; 38: 1460-1465.
81. Yeaman MR, Cheng D, Desai B, et al. Susceptibility to thrombin-induced platelet microbicidal protein is associated with increased fluconazole efficacy against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 2004; 48: 3051-3056.
82. Perkhofer S, Striessnig B, Sartori B, et al. Interaction of platelets and anidulafungin against Aspergillus fumigatus. Antimicrob Agents Chemother 2013; 57: 626-628.
83. Perkhofer S, Trappl K, Nussbaumer W, et al. Potential synergistic activity of antimycotic substances in combination with human platelets against Aspergillus fumigatus. J Antimicrob Chemother 2010; 8: 1309-1311.
84. Perkhofer S, Trappl K, Striessnig B, et al. Platelets enhance activity of antimycotic substances against non-Aspergillus fumigatus Aspergillus species in vitro. Med Mycol 2011; 49: 157-166.
85. Heller I, Leitner S, Dierich MP, et al. Serotonin (5-HT) enhances the activity of amphotericin B against Aspergillus fumigatus in vitro. Int J Antimicrob Agents 2004; 24: 401-404.
86. Cossu AP, Musu M, Mura P, et al. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol 2014; 70: 23-28.
87. Hansson EK, Wallin JE, Lindman H, et al. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 2010; 65: 839-848.
88. Arnold DM, Nazi I, Warkentin TE, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27: 137-145.
89. Pavanetto M, Zarpellon A, Giacomini D, et al. Inhibitory effect by new monocyclic 4-alkyliden-beta-lactam compounds on human platelet activation. Platelets 2007; 18: 357-364.
90. Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38: 865-883.